Novo Nordisk is ”very enagaged” in India, the CFO says, but the weight-loss drug will not be launched there until 2025.
Photo: Tom Little
BY CHRISTIAN BUNDGAARD
28 May 2024
at 09:50
People with obesity in India will have to wait to get access to Novo Nordisk’s big seller Wegovy, according to the local Indian media Business Today, which has spoken to Novo Nordisk CFO Karsten Munk Knudsen.”As far as the timeline for the launch of Wegovy in India is concerned, unfortunately it will not be this year,” Knudsen says to the media, adding: ”We are very committed to the Indian market and the unmet need in diabetes and obesity is high in India as in many other markets.”Since the approval of Wegovy for obesity, Novo Nordisk has been strategically cautious about entering new markets. This is largely due to difficulties in keeping up with demand in markets where the drug has already been launched.Novo Nordisk has previously fought a battle in India to stop unauthorized advertisements for Wegovy in the country, and several local generics manufacturers are already developing their own versions of the drug.English edit: Catherine Brett
Leave a Reply